



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

We declare no competing interests.

\*Patricia Schlagenhauf, Jeremy Deuel  
patricia.schlagenhauf@uzh.ch

University of Zürich Centre for Travel Medicine, WHO Collaborating Centre for Travellers' Health, MilMedBiol Competence Centre, Department of Public and Global Health, Epidemiology, Biostatistics and Prevention Institute, Zürich, Switzerland (PS); University of Zürich, MilMedBiol Competence Centre, Department of Public and Global Health, Epidemiology, Biostatistics and Prevention Institute, Zürich, Switzerland (JD); University Hospital of Zurich, Division of Medical Oncology and Haematology, Zürich, Switzerland (JD)

- 1 Delaugerre C, Foissac F, Abdoul H, et al. Prevention of SARS-CoV-2 transmission during a large, live, indoor gathering (SPRING): a non-inferiority, randomised, controlled trial. *Lancet Infect Dis* 2021; published online Nov 26. [https://doi.org/10.1016/S1473-3099\(21\)00673-3](https://doi.org/10.1016/S1473-3099(21)00673-3).
- 2 Jonsdottir HR, Bielecki M, Siegrist D, Buehrer TW, Züst R, Deuel JW. Titers of neutralizing antibodies against SARS-CoV-2 are independent of symptoms of non-severe COVID-19 in young adults. *Viruses* 2021; **13**: 284.

- 3 Dinnes J, Deeks JJ, Berhane S, et al. Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. *Cochrane Database Syst Rev* 2021; **3**: CD013705.
- 4 Hendrix MJ, Walde C, Findley K, Trotman R. Absence of apparent transmission of SARS-CoV-2 from two stylists after exposure at a hair salon with a universal face covering policy—Springfield, Missouri, May 2020. *MMWR Morb Mortal Wkly Rep* 2020; published online July 14. [https://www.cdc.gov/mmwr/volumes/69/wr/mm6928e2.htm?s\\_cid=mm6928e2](https://www.cdc.gov/mmwr/volumes/69/wr/mm6928e2.htm?s_cid=mm6928e2).
- 5 Elachola H, Ebrahim SH, Gozzer E. COVID-19: Facemask use prevalence in international airports in Asia, Europe and the Americas, March 2020. *Travel Med Infect Dis* 2020; **35**: 101637.
- 6 Tang JW, Marr LC, Li Y, Dancer SJ. Covid-19 has redefined airborne transmission. *BMJ* 2021; **373**: n913.
- 7 The Whispers (1979). And the beat goes on. Los Angeles, CA: Sound of Los Angeles Records.

## SARS-CoV-2 delta variant: a persistent threat to the effectiveness of vaccines

Vaccine effectiveness studies are important tools to assess the usefulness of vaccines during the post-approval period in the real-world context. Global experience in evaluating many previous vaccines has enabled formulation of best practices and guidelines for conducting such observational epidemiological studies in a short time frame,<sup>1</sup> to guide immunisation policies. These studies are of particular importance during the COVID-19 pandemic, where the roll-out of vaccines has been much faster than usual.

In *The Lancet Infectious Diseases*, Devashish Desai and colleagues<sup>2</sup> report the findings from their test-negative, case-control, vaccine effectiveness study of a whole-virion inactivated SARS-CoV-2 vaccine, BBV152, during the peak of the second wave of the COVID-19 pandemic in New Delhi, India, which was presumably driven by the delta (B.1.617.2) variant. The adjusted vaccine effectiveness against symptomatic COVID-19 after two doses of BBV152, with the second dose administered at least 14 days before RT-PCR testing, was 50% (95% CI 33–62). This is, to our knowledge, a first independent report on the vaccine effectiveness of BBV152, which is being administered to millions of people in India and other low-income and middle-income countries.<sup>3</sup> The key message of the study is the reduced effectiveness of BBV152, even with two doses of vaccine, against SARS-CoV-2 infections attributed to the delta variant compared with the effectiveness

against the wild type (77.8% [95% CI 65.2–86.4]) that was reported in the phase 3 trial.<sup>4</sup> It is important to note that the vaccine effectiveness estimated was not against delta variant infections only, but against infections that occurred during the surge in SARS-CoV-2 cases dominated by the delta variant.<sup>5</sup>

A strength of the study by Desai and colleagues is the test-negative, case-control design in an organised study population—employees of a tertiary-level health-care institution—who were offered unbiased vaccination and testing services. The study has some methodological limitations, such as absence of comorbidity data and no objective assessment of previous infection, as discussed by the authors. The decline in vaccine effectiveness against SARS-CoV-2 infection during a delta-driven surge in cases is neither surprising nor exclusive to inactivated SARS-CoV-2 vaccines including BBV152. The delta variant has high transmissibility, infectivity, and virulence, which causes severe disease.<sup>5,6</sup> These attributes might have contributed to a reduced vaccine effectiveness against symptomatic infections, which has been reported to be as low as 56% for other vaccines in multiple studies worldwide.<sup>7,8</sup> Furthermore, this study was conducted in a high-risk population with a high exposure to SARS-CoV-2 in a tertiary care hospital caring for patients with COVID-19, in the context of a massive surge in infections, with high test-positivity rates of up to 34%, which could have been



Published Online  
November 23, 2021  
[https://doi.org/10.1016/S1473-3099\(21\)00697-6](https://doi.org/10.1016/S1473-3099(21)00697-6)  
See [Articles](#) page 349

the key factor for the observed reduction in vaccine effectiveness.

Although BBV152 might not be as effective against symptomatic infection by the delta variant as it was against the wild type, a more useful outcome of vaccination is the protection against moderate and severe COVID-19. Moderate-to-severe disease warrants hospitalisation and intensive medical care, and therefore puts strain on health-care systems. Vaccination has been shown to protect against hospitalisation and death, even during the delta surge.<sup>7</sup> This study does not provide evidence in this regard. But, if one were to consider vaccine effectiveness studies for other inactivated vaccines which indicated a better protection against moderate-to-severe disease than infection, it could be presumed that BBV152 might also have a similar performance.<sup>9,10</sup> Future studies should be designed with the emphasis to evaluate protection against moderate-to-severe COVID-19 and to analyse immune correlates of protection, such as neutralising antibodies and antigen-specific T-cell response, against the wild type and the delta variant in BBV152-vaccinated individuals. This emphasis might provide evidence on the need for a booster dose, especially in populations with comorbid conditions. Nevertheless, faced with the challenge of protecting as much of the population as possible, the ongoing vaccination drive should be continued as a public health intervention against SARS-CoV-2, along with strict adherence to other non-pharmacological

interventions, particularly in the context of variant-driven surges.

We declare no competing interests.

Ramachandran Thiruvengadam†, Akshay Binayke†, \*Amit Awasthi

aawasthi@thsti.res.in

†Contributed equally

Translational Health Science and Technology Institute, Faridabad, India

- 1 WHO. Evaluation of COVID-19 vaccine effectiveness. Geneva: World Health Organization, 2021.
- 2 Desai D, Khan AR, Soneja M, et al. Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study. *Lancet Infect Dis* 2021; published online Nov 23. [https://doi.org/10.1016/S1473-3099\(21\)00674-5](https://doi.org/10.1016/S1473-3099(21)00674-5).
- 3 Government of India Ministry of Health and Family Welfare. Co-WIN dashboard: India COVID-19 vaccination status. 2021. <https://dashboard.cowin.gov.in/> (accessed Sept 29, 2021).
- 4 Ella R, Reddy S, Blackwelder W, et al. Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial. *Lancet* 2021; published online Nov 11. [https://doi.org/10.1016/S0140-6736\(21\)02000-6](https://doi.org/10.1016/S0140-6736(21)02000-6).
- 5 Dhar MS, Marwal R, Vs R, et al. Genomic characterization and epidemiology of an emerging SARS-CoV-2 variant in Delhi, India. *Science* 2021; **0**: eabj9932.
- 6 Fisman DN, Tuite AR. Evaluation of the relative virulence of novel SARS-CoV-2 variants: a retrospective cohort study in Ontario, Canada. *CMAJ* 2021; **193**: E1619–25.
- 7 Harder T, K ulper-Schiek W, Reda S, et al. Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection with the delta (B.1.617.2) variant: second interim results of a living systematic review and meta-analysis, 1 January to 25 August 2021. *Euro Surveill* 2021; **26**: 2100920.
- 8 Reis BY, Barda N, Leshchinsky M, et al. Effectiveness of BNT162b2 vaccine against delta variant in adolescents. *N Engl J Med* 2021; published online Oct 20. <https://doi.org/10.1056/NEJMc2114290>.
- 9 Wang F, An Z, Rodewald L, et al. Guangdong's study of the effectiveness of China's inactivated vaccines against the SARS-CoV-2 B.1.617.2 (delta) variant. *China CDC Wkly* 2021; **3**: 728–30.
- 10 Li X-N, Huang Y, Wang W, et al. Effectiveness of inactivated SARS-CoV-2 vaccines against the delta variant infection in Guangzhou: a test-negative case-control real-world study. *Emerg Microbes Infect* 2021; **10**: 1751–59.



## Rapid COVID-19 vaccine rollout: immense success but challenges ahead



Flickr - Zierveez

In *The Lancet Infectious Diseases*, Eric Haas and colleagues<sup>1</sup> estimated the benefits of the rapid mass roll-out of the Pfizer-BioNTech vaccine in Israel between Dec 20, 2020, and April 10, 2021. They found substantial benefits of the vaccine in terms of preventing thousands of deaths, hospitalisations, and new SARS-CoV-2 infections in individuals aged 16 years and older.<sup>1</sup> Thanks to the successful vaccination programme, non-pharmaceutical restrictions were gradually lifted in Israel in February–March, 2021,<sup>1,2</sup> and the national economy is reported to have recovered in April–June 2021, with an estimated economic growth of more than 5.5% forecasted for 2021.<sup>3</sup>

The mass COVID-19 vaccination roll-out in Israel has been followed with great interest internationally because it was the fastest roll-out globally, and achieved high levels of vaccine uptake within a few months.<sup>1</sup> The vaccination programme was introduced at the beginning of a new outbreak wave in Israel in December, 2020, when the alpha (B.1.1.7) variant was predominant.<sup>1,2</sup> The authors report that nearly 74% of individuals aged 16 years or older in Israel had received two vaccine doses by April 10, 2021,<sup>1</sup> increasing to 81% by June 1, 2021.<sup>2</sup> Despite a new outbreak wave caused by the delta (B.1.617.2) variant in Israel, with case

Published Online  
September 22, 2021  
[https://doi.org/10.1016/S1473-3099\(21\)00616-2](https://doi.org/10.1016/S1473-3099(21)00616-2)

See [Articles](#) page 357